{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-041652","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2023-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.406992+00:00","generated_at":"2026-06-08T01:08:07.903873+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Processa Pharmaceuticals presents at Orphan Drugs Congress; no material new data disclosed","bullets":["Dr. David Young, President of R&D, presented on Nov 16, 2023 at 2:40 PM ET at the 20th Orphan Drugs and Rare Diseases Global Congress in Boston.","Presentation title: 'Benefit-Risk Analysis for FDA Approval Requires More Than a Pivotal Trial'.","Presentation furnished as Exhibit 99.1 but exhibit text not provided; no specific numbers, milestones, or guidance detailed in the 8-K.","Company undertakes no obligation to update this Reg FD disclosure; no changes to business or financial condition reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-041652","json":"https://secwatch.observer/filing/0001493152-23-041652.json","markdown":"https://secwatch.observer/filing/0001493152-23-041652.md","text":"https://secwatch.observer/filing/0001493152-23-041652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223041652/0001493152-23-041652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315223041652/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T01:08:07.903873+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}